A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its recently appointed Impact Council In three years' time, Gilde Healthcare raised over €1.5 billion across three funds Gilde Healthcare today announces a new investment fund with €600 million in commitments: Gilde Healthcare Venture&Growth VI. The new fund foc

TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, announced today its public launch and the closing of a $158 million Series B financing. TORL's pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) were discovered in the laboratory of scientific co-founder Dennis Slamon, M.D., Ph.D., Professor of Medicine, and Chief of the Division of Hematology/Oncology at UCLA's David Geffen School of Medicine (DGSOM).

Alentis Therapeutics, a biotech pursuing a novel target as a way of treating fibrosis and cancer, has raised $105 million for clinical trials in both. The focus of Alentis’s drug research is Claudin 1 (CLDN1), a member of the tight junctions family of proteins. These proteins are found in the cells that line blood vessels, as well as the cells that cover body surfaces and line hollow organs. Too much production of CLDN1 can cause signaling in organs that lead to disease. Basel, Switzerland-base

Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors Funding to advance clinical development of two first-in-class anti-CLDN1 antibodies and the platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies Series C led by Jeito Capital together with Novo Holdings and RA Capital Management Naveed Siddiqi, Senior Partner at Novo Holdings, joins the Board of Directors Novo Holdings A/S,

Samsung Ventures makes investment in Araris Proceeds will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Samsung Venture Investment Corporation (“Samsung Ventures”), an investment corporation established to promote the development of new technologies, has invested in the Company in an i

Pear Therapeutics’ search for a buyer has yet to lead to a consummated deal, and the beleaguered digital therapeutics company is now looking to auction off the business or its assets under the protection of Chapter 11 bankruptcy. The bankruptcy filing announced Friday followed financial struggles that included three corporate restructurings in the span of less than a year. The most recent restructuring, implemented last week, led to the layoff of 170 employees representing about 92% of Pear’s w

BioNTech has turned to dealmaking yet again to diversify its cancer drug pipeline, paying $170 million to begin an alliance with Duality Biologics. The deal includes a clinical-stage drug candidate with the potential to compete against an AstraZeneca medicine whose recent expanded approvals in breast and lung cancers position it become a blockbuster seller. The upfront payment gives BioNTech global rights to two DualityBio drug candidates. According to terms of the deal announced Monday, the Ge

– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic financings strengthen the company’s balance sheet in advance of potential commercialization of LUMRYZ Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its entry into a royalty agreement with RTW Investments, LP and certain of its affiliates (“RTW”) for up to $75 million to support the potential commerciali

Despite a tough financing market, ArriVent Biopharma closed a $155 million Series B to fund a pivotal Phase III trial of its non-small cell lung cancer asset. The funding comes at a time when Series B deals are significantly down. Crunchbase shows that in Q1 of 2023, U.S. companies are on track for a record low compared to the past nine quarters. The company is developing a brain-penetrant EGFR tyrosine kinase inhibitor (TKI) that targets EGFR-activating mutations in NSCLC. Licensed from partne

--Financing round led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from a world-class group of investors-- --Proceeds to support advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare's platform and pipeline of novel transcription factor targets in oncology-- Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other disease